Aphaia Pharma has announced that its Phase II trial of APHD-012 met its primary endpoint.
The clinical-stage biotech is focused on precision-targeted drug formulations for obesity and metabolic diseases.
APHD-012 works by targeting nutrient-sensing cells in the distal small intestine and activating them to induce the release of hormones that regulate key metabolic processes.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze